Prophylactic tocilizumab was administered 30 minutes prior to receiving CAR-T cells for both cohorts. There were three dose levels (DL): 0.5 x 10e6/kg, 1.0x 10e6/kg and 2.0 x 10e6/kg. Results : 17 patients were eligible and 16 started lymphodepleting chemotherapy. Successful product ...
Several approaches focusing on T-cell mediated myeloma cell killing, such as CAR-T-cells2 and bispecific T-cell engagers3 are currently being investigated as therapy for these patients. In addition, the introduction of anti-CD38 mAbs (ie, daratumumab and isatuximab) has significantly influenced ...
We achieve this through various, targeted treatment modalities and biology interventions, including small molecule therapeutics, antibody-drug conjugates (ADCs), immuno-oncology-based therapeutics, multispecific antibody and in situ CAR-T platforms. Our dedicated an...
targeted treatment modalities and biology interventions, including small molecule therapeutics, antibody-drug conjugates (ADCs), immuno-oncology-based therapeutics, multispecific antibody and in situ CAR-T platforms. Our dedicated and experienced team jo...
Despite the significant therapeutic advances provided by immune-checkpoint blockade and chimeric antigen receptor T cell treatments, many malignancies remain unresponsive to immunotherapy. Bispecific antibodies targeting tumor antigens and activating T c
targeted treatment modalities and biology interventions, including small molecule therapeutics, antibody-drug conjugates (ADCs), immuno-oncology-based therapeutics, multispecific antibody and in situ CAR-T platforms. Our dedicated and experienced team joins forces with innovative partners to accelerate the de...
2、anti-CD3ε 激动剂抗体可以引起 T 细胞激活并释放细胞因子,但是这类抗体也有一些限制因素。第一,高亲和力的抗体会激活高水平的细胞因子释放,导致细胞因子风暴,这也是 CAR-T 和 T 细胞连接子的负反应;第二,CD3 激活是 T 细胞分化的两个信号之一,但是只激活这一个信号会导致激活的细胞死亡,限制了长久的抗肿...
SAR442257, a CD38/CD28/CD3 trispecific antibody, potentiates CAR T-cell activity against large B-cell lymphoma The CD38/CD28xCD3 trispecific antibody SAR442257 boosted CART-cell activity through recognition of CD38 on the tumor, costimulation of CART-cells, and induced fratricide of...
targeted treatment modalities and biology interventions, including small molecule therapeutics, antibody-drug conjugates (ADCs), immuno-oncology-based therapeutics, multispecific antibody and in situ CAR-T platforms. Our dedicated and experienced team jo...
Article Open access 11 January 2022 IL-27 elicits a cytotoxic CD8+ T cell program to enforce tumour control Article 05 February 2025 Acquired cancer cell resistance to T cell bispecific antibodies and CAR T targeting HER2 through JAK2 down-modulation Article Open access 23 February 2021 Data...